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Abstract: This study aimed to examine the effects of tualang honey against the high cholesterol diet 
induced biochemical and histological changes in the kidney, liver and pancreas. Methods: Female 
Sprague-Dawley rats were used where the control group (n = 5) was fed with commercial rat pellet; the 
high cholesterol diet (HCD) group (n= 5) was given 12% cholesterol diet; while the HCD with tualang 
honey (HCD+TH) group (n =5) was fed with 12% cholesterol diet with daily 1.4 g/kg/day of tualang 
honey. Biochemical analyses for lipid profile and renal function test were performed at completed 48 
hours, 7 days, and 6 weeks. The rats were sacrificed at completed 6 weeks and the kidneys were harvested 
and subjected to histopathological examination. Blood biochemical analysis were also analysed at 1 week 
and 6 weeks for liver function test, fasting insulin, fasting glucose and HOMA-IR. The liver and pancreas 
tissues were harvested at the end of 6 weeks for histological examination. Results: The cholesterol diet 
induction resulted in dyslipidaemia and abnormal liver function. The HCD+TH group have shown an 
increase in total cholesterol, LDL-c, ALP levels and decreased TG, HDL-c and AST levels significantly 
at the end of 6 weeks compared to HCD group. Consumption of 12% cholesterol diet for six weeks 
resulted in an increment of the mean serum creatinine level of the HCD and HCD+TH groups to 1.5 times 
the control level at the completed 7 days. Also overall both the mean serum creatinine and blood urea 
levels were higher in HCD group than the control group. With tualang honey supplementation, the mean 
serum creatinine level showed significant reduction at 48 hours in the HCD+TH group as compared to the 
HCD group. There was also a reduction in the mean serum creatinine level at the completed 6 weeks. . 
Histopathologically the kidneys exhibited segmental mesangial hypercellularity and mesangial matrix 
expansion of almost all the glomeruli in both HCD and HCD+TH groups. The mean plasma glucose level 
was elevated at 1 week in the HCD group. Plasma insulin levels were higher in HCD+TH group at both 1 
and 6 weeks. The HOMA-IR was also higher at 1 week in the HCD+TH group. The liver histology of 
both HCD and HCD+TH groups showed steatohepatitis with minimal hepatocyte degeneration while the 
pancreatic sections revealed no abnormalities. Conclusion: The 12% cholesterol diet of 6 weeks duration 
in this study did induce some features of NASH with dyslipidaemia with abnormal liver profile and also 
acute kidney injury.  The tualang honey exerts some degree of renoprotective effect against high 
cholesterol diet induced kidney injury, but exhibited no effect on dyslipidaemia and histopathological 
changes in liver and pancreas. 
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Introduction 
Kidney diseases include acute kidney injury (AKI), sub-acute kidney injury, and chronic kidney 
disease (CKD). For AKI more than 35 definitions have been used in the literature. This results in 
confusion and ill-defined association between acute renal dysfunction and morbidity and mortality 
(Mandelbaum et al., 2011). AKI is characterized by rapid and sometimes fatal loss of kidney function, 
leading to inability to maintain body fluids, electrolytes and acid-base homeostasis, and causing 
accumulation of end products of nitrogen metabolism (urea) and creatinine, or reduction in urine output, 
or both (Bellomo, Kellum, & Ronco, 2012). It is also defined as an abrupt reduction in the glomerular 
filtration rate (GFR) which results in accumulation of nitrogenous waste products, mainly creatinine and 
blood urea nitrogen (BUN) (Basile, Anderson, & Sutton, 2012). 
However the preferred definition and staging system of AKI is the most recent proposed definition 
by the Kidney Disease: Improving Global Outcomes (KDIGO). According to KDIGO guidelines (2012), 
AKI defined as an increase in serum creatinine (SCr) by ≥0.3 mg/dl (≥26.5 μmol/l) within 48 hours; or 
increase in SCr to ≥1.5 times baseline, which is known or presumed to have occurred within the prior 7 
days; or urine volume < 0.5 ml/kg/h for 6 hours (Kidney Disease: Improving Global Outcomes (KDIGO) 
Acute Kidney Injury Work Group, 2012). KDIGO guidelines proposed the term, acute kidney diseases 
and disorders (AKD), to include any decline in renal function occurring in less than three months. 
Disorders that evolve over more than 48 hours, but generally under than three months are referred to as 
sub-acute kidney injury. AKD includes both AKI and sub-acute kidney injury, and there is considerable 
overlap in an acute and sub-acute presentation (Pedram Fatehi, 2016). 
The incidence of AKD is on the rise in both developed and developing countries (Lameire et al., 
2013), and it has been proven that diet and lifestyle have an important role in its development. High 
cholesterol diet (HCD) has been documented to causes elevation of blood pressure and induce renal injury 
(Al-Rejaie, Abuohashish, Alkhamees, Aleisa, & Alroujayee, 2012). Researchers have proven that there 
exists a complex association between progressive renal damage and hypercholesterolemia (Ghada, 2014). 
These findings are of concerns as approximately 50% of the middle-aged adult population has been 
shown to have total cholesterol levels above the normal range (Chade et al., 2005). Most previous studies 
however focused on the impact of chronically high blood cholesterol levels on the renal tissue. One of 
them revealed that hypercholesterolemia resulted in the development of focal glomerulosclerosis and 
proteinuria that rapidly progressed to renal failure (Deepa & Varalakshmi, 2006). 
In essence there is minimal information available in the literature with regard to early effects of 
hypercholesterolemia on the kidney (Abdel-Hafez, Othman, & Seleim, 2011). Also although there is a 
growing insight into the causes and mechanisms of the kidney diseases, preventive and therapeutic 
measures are still few (Lameire et al., 2013).  
The persence of hepatic steatosis in the absence of significant use of alcohol or other liver disease 
is the characteristic feature of Nonalcoholic fatty liver disease (NAFLD). The progressive form of 
NAFLD is known as  Nonalcoholic steatohepatitis (NASH) (Vernonet al., 2011) which can be diagnosed 
by the presence of of steatosis, inflammation and hepatocellular ballooning on liver biopsies (Bruntet al., 
2012). NAFLD is a leading cause to cirrhosis, liver failure, and hepatocellular carcinoma (Adams et al., 
2005). Insulin resistance, oxidative stress and lipid peroxidation, proinflammatory cytokines, adipokines 
and mitochondrial dysfunction play an important role in the development and progression of NAFLD 
(Paschos & Paletas, 2009). In addition NAFLD is considered as the hepatic manifestation of the 
metabolic syndrome (TARGHER et al., 2007). NAFLD scoring system proposed by the Pathology 
Committee of the NASH Clinical Research Network comprised 14 histological features, 4 of which were 
evaluated semi-quantitatively: steatosis (0-3), lobular inflammation (0-2), hepatocellular ballooning (0-2), 
and fibrosis (0-4). Another nine features were recorded as present or absent (Kleiner et al., 2005). 
NAFLD is considered to be the most common cause of elevated liver enzymes (Vernon et al., 2011).  
Honey has been used since ancient times to treat several diseases due to its medicinal importance 
(Tan et al., 2009).  Tualang honey is a type of Malaysian polyfloral wild honey (Othman et al., 2015) rich 
in phenolic acids and flavonoid compounds which have strong free radical-scavenging activities (Khalil, 
et al., 2011). Tualang honey has a good anti-bacterial (Shehu et al., 2015) and anti-inflammatory activities 
(Al-Waili & Boni, 2003). It has a considerable effect on the healing process of different types of wounds 
(Khoo et al., 2010). It has been used in the treatment of diabetic foot (Imran et al., 2011). Tualang honey 
demonstrates a significant antioxidant activity (Shehu et al., 2015). It also has a significant anti-neoplastic 
activity (Yaacob et al, 2013) and a potential role in the improvement of learning and memory (Othman et 
al., 2015). It has cardioprotective (Khalil et al., 2015) and renoprotective (Mohamed et al., 2017) 
activities. In an experimental study, tualang honey produced a hepatoprotective effect (Erejuwa et al., 
2011). As no drug therapy for NASH has been proved (Farrell & Larter, 2005), we aimed in this study to 
determine the possible hepatoprotective effects of tualang honey against high cholesterol diet induced 
NASH. 
Objectives: 
 To determine the acute and sub-acute effects of high cholesterol diet on the kidney in rat animal 
model 
 To determine the protective effects of orally administered tualang honey on HCD induced AKD in 
animal rat model. 
 To determine the effects of high cholesterol diet on the liver and pancreas biochemically and 
histologically.  
 To examine the protective effects of tualang honey against the high cholesterol diet induced 
biochemical and histological changes.   
 
 
 
Methodology:  
Animals 
Fifteen female Sprague-Dawley rats (age 6- 8 weeks) weighing 140 -170 grams were used in this study. 
The rats were purchased from A-Sapphire Enterprise, Seri Kembangan, Selangor. Two rats were housed 
in each cage under standard experimental conditions of 20 - 26°C at 50 - 70% humidity with 12 hours 
light/dark cycles. Throughout the experiment, the animals were given free access of water and food. The 
experimental protocols were approved by the Institutional Animal Care and Use Committee, International 
Islamic University Malaysia (IACUC-IIUM) No. of IACUC Approval : IIUM / IACUC Approval / 2016/ 
(12) (83). 
High cholesterol diet  
Twelve percent cholesterol diet was prepared by mixing 1kg of commercial rat pellet in powder form 
with 120 grams of analytical pure cholesterol powder (Nacalai-Tesque, Kyoto, Japan. Lot No. M4T5494. 
Code 08721-75). Three grams of cholic acid (Nacalai-Tesque, Kyoto, Japan. Lot No. M6H9123. Code 
08805-56) were added to the preparation in order to produce stable hypercholesterolemia (Monte & 
Jimenez, 1993). In order to avoid oxidative modification of the cholesterol, the preparation of the high 
cholesterol diet was carried out on a weekly basis. 
Tualang honey 
Tualang honey (AgroMas, Malaysia) was supplied by Federal Agricultural Marketing Authority (FAMA), 
Kedah, Malaysia. The nutritional composition and specifications of tualang honey are as shown in table 1. 
The honey dose was calculated by conversion of human equivalent dose to rat dose using Km factor 
(Reagan-Shaw et al., 2008) according to as the following: 
Human equivalent dose (HED) = Animal dose × Animal Km factor/ Human Km factor  
(Reagan-Shaw et al., 2008) 
Table 1: Nutritional composition and specifications of tualang honey 
Parameter, Unit Result Standard (Food Reg 
1985,Reg. 130) 
Reducing Sugar (g/100g): 
 Fructose 
 Glucose 
 
38.0  
36.9 
>60.0 
Sucrose (g/100g) Not detected (<0.01) <10.0 
Ash (g/100g) 0.02 <1.0 
Moisture (g/100g) 23.1 <20.0 
Experimental design  
 Following 10 days of acclimatization, the animals were randomly divided into three groups. Group I 
served as a control group (n=5) and was fed with commercial rat pellet. Group II served as the high 
cholesterol diet (HCD) group (n=5) and was fed with 12% cholesterol diet. Group III (n=5, HCD+TH) 
was fed with 12% cholesterol diet along with oral daily dose of 1.4 g/kg/day of tualang honey by gavage. 
The experimental diets were administered for 6 weeks. 
Biochemical study 
Blood specimens collected at completed 48 hours, 7 days and 6 weeks were analysed for lipid profile and 
renal function test (Siemen Xpand Plus, USA). 
Blood specimens were also collected, after overnight fasting, at 1 week and 6 weeks were analysed for 
liver function test (Siemen Xpand Plus, USA), fasting plasma glucose (MEDISAFE MINI Blood Glucose 
Reader, Japan) and fasting serum insulin (radioimmunoassay method). The homeostasis model 
assessment of insulin resistance (HOMA-IR) index was calculated using the formula below:  
HOMA1-IR = fasting serum insulin (μU/ml) x fasting plasma glucose (mmol/L)/22.5  
(Matthews et al., 1985) 
Histological study 
At 6 weeks, all rats were euthanized and the kidney, liver and pancreas of each of the animals were 
harvested and fixed in 10% neutral buffered formalin for histological examination. The liver and pancreas 
tissues were processed using automated tissue processor (Leica TP 1020). The tissues were embedded 
into paraffin blocks (Leica EG1160). They were sectioned at 4 μm thickness and stained with 
hematoxylin and eosin (H&E) and Masson trichrome. 
Statistical analysis  
Statistical analysis was performed using ANOVA (SPSS version 20.0) to compare the biochemical blood 
results of the study groups. A value of p<0.05 was considered to be significant. The histological sections 
were analysed by two pathologists. 
 
 
 
 
 
 
 
 
 
 
Results 
Table 2. Lipid profile in the HCD and HCD+TH groups of rats 
Lipid Profile  
parameter 
(mmol/L) 
 
48-hours 7 Days 6 week 
 HCD HCD+TH HCD HCD+TH HCD HCD+TH 
Cholesterol  
 
2.30±0.40 
 
2.40±0.69 2.84±0.68   1.83±0.71* 7.38±2.93 8.76±4.07 
HDL-c 
 
1.88±0.21 2.03±0.32 2.45±0.65 2.11±0.95 0.23±0.10 0.18±0.08 
Triglyceride 
 
vLDL-c 
0.50±0.20 
 
0.10±0.04 
0.41±0.17 
 
0.08±0.03  
0.44±0.10 
 
0.08±0.02 
0.28±0.11* 
 
0.05±0.02 
0.53±0.15 
 
0.11±0.03 
0.53±0.11 
 
0.11±0.02 
       
Values are given as means ± sd. Significant differences were analysed using Student’s t-test, and 
indicated as *p<0.05 when comparing HCD with HCD+TH rats. 
Table 3. Renal profile in the HCD and HCD+TH groups of rats 
Renal 
Profile 
parameter 
 
48-hours 7 Days 6 week 
 HCD HCD+TH HCD HCD+TH HCD HCD+TH 
Creatinine 
(µmol/L) 
 
33.40±9.15 15.60±9.9* 25.20±12.80 25.40±10.03 40.60±4.28 34.80±3.83 
Urea  
(mmol/L) 
 
4.56±1.05 4.46±0.87 9.24±4.07 6.26±1.15 9.76±4.20 7.98±0.68 
Sodium 
(mmol/L) 
 
137.40±0.55 137.60±1.67 136.80±2.17 138.20±1.30 139.20±2.05 138.80±0.84 
Potassium 
(mmol/L) 
 
5.38±0.29 5.54±0.88 7.18±1.86 5.96±0.78 4.40±0.48 5.10±0.38 
Chloride 
(mmol/L) 
 
100.40±0.55 101.00±1.22 100.20±0.84 100.00±1.22 99.80±1.48 99.40±0.55 
Uric acid 
(mmol/L) 
 
0.11±0.05 0.26±0.26 0.16±0.04 0.19±0.07 0.13±0.03 0.13±0.02 
Values are given as means ± sd. Significant differences were analysed using student t-test, and indicated 
as *p<0.05 when comparing HCD with HCD+TH groups of rats. 
 
Table 4. Liver function test.                                                                                                                
Values are given as means ± sd. Significant differences were analysed using ANOVA test, 
and indicated as *p<0.05 when comparing control with HCD and HCD+TH groups. 
 
Table 5. Fasting glucose, Insulin, and HOMA-IR  
Parameters 
 
                     1 week                  6 weeks 
 Control HCD HCD+TH Control HCD HCD+TH 
Plasma 
glucose 
(mmol/L) 
 
6.02±0.69* 7.82±1.80*   6.86±0.86 7.34±1.04   6.90±0.95 6.92±0.97 
Serum 
insulin  
(uU/ml) 
 
0.34±0.17* 0.46±0.15 0.68±0.16* 0.52±0.23* 0.56±0.17 0.78±0.13* 
HOMA-IR 
 
0.09±0.06* 0.16±0.06 0.20±0.05* 0.17±0.08 0.17±0.07 0.24±0.05 
Values are given as means ± sd. Significant differences were analysed using ANOVA test, 
and indicated as *p<0.05 when comparing control with HCD and HCD+TH groups. 
 
 
 
Liver profile 
parameters 
 
1 week 6 weeks 
 Control HCD HCD+TH Control HCD HCD+TH 
Albumin (g/L) 
 
13.4±0.55 12.80±1.79 12.80±1.92 37.8±1.30 39.40±2.07 40.00±3.39 
Total bilirubin 
(umol/L) 
 
3.40±0.55 3.40±0.89 3.20±1.10 2.00±0.00 2.00±0.00 2.00±0.00 
Alkaline 
phosphatase 
(U/L) 
 
231.40±42.88 343.40±77.80* 337.40±22.84* 144.40±32.85 200.60±46.67* 209.00±37.88* 
 GGT (U/L) 
 
 
3.40±2.51 3.00±1.41 3.80±2.56 3.20±0.45 3.60±0.89 3.40±0.55 
AST (U/L) 279.20±31.14 374.40±99.28 329.20±74.11 169.60±19.48 264.40±48.27* 200.80±40.21* 
ALT (U/L) 53.60±3.65 48.00±23.84 62.60±19.42 47.80±3.96 54.80±7.76 52.80±9.68 
Renal histology 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Liver histology 
 The control group showed normal liver histology. The sections of the livers from the HCD group and 
HCD+TH group showed areas of microvesicular steatosis with mild lobular and portal inflammation 
(Figure 1). Hepatocyte degeneration was minimal. Sections of the liver stained with Masson Trichrome 
stain from all the groups revealed no areas of fibrosis (Figure 1). 
 
Figure 1: (A): Section of the liver from control group (Haematoxylin and Eosin stain, x20 objective). The 
section showed normal liver histology. (B): Section of the liver from high cholesterol diet group 
(Haematoxylin and Eosin stain, x20 objective). The section showed microvesicular steatosis (arrow) with 
lobular and portal inflammation (arrow head). (C): Section of the liver from high cholesterol diet with 
Tualang honey group (Haematoxylin and Eosin stain, x20 objective). The section showed microvesicular 
steatosis (arrow) with mild lobular inflammation (arrow head). (D): Section of the liver from control 
group (Masson Trichrome stain x10 objective). The section showed no area of fibrosis. (E): Section of the 
liver from high cholesterol diet group (Masson Trichrome stain x10 objective). The section showed no 
area of fibrosis. (F): Section of liver from high cholesterol diet with Tualang honey group (Masson 
Trichrome stain x10 objective). The section showed no area of increased of fibrous tissue formation. 
 
 
 
 
Pancreatic histology  
Sections of the pancreatic tissues from the control group, HCD group, and HCD+TH group all revealed 
normal pancreatic glands. Sections of the pancreatic tissue stained with Masson Trichrome stain from the 
three groups showed no areas of increased amount of fibrous tissue formation (Figure 2).  
 
Figure 2: (A): Section of the pancreatic gland from control group (Haematoxylin and Eosin stain, x20 
objective). The section showed normal pancreatic gland. (B): Section of the pancreatic gland from high 
cholesterol diet group (Haematoxylin and Eosin stain, x20 objective). The section showed normal 
pancreatic gland. (C): Section of the pancreatic gland from high cholesterol diet with Tualang honey 
group (Haematoxylin and Eosin stain, x20 objective). The section showed normal pancreatic gland. (D): 
Section of the pancreatic gland from control group (Masson Trichrome stain x10 objective). The section 
showed no area of increased amount of fibrous tissue formation. (E): Section of the pancreatic gland from 
high cholesterol diet group (Masson Trichrome stain x10 objective). The section showed no area of 
increased amount of fibrous tissue formation. (F): Section of pancreatic gland from high cholesterol diet 
with Tualang honey group (Masson Trichrome stain x10 objective). The section showed no area of 
increased of fibrous tissue formation. 
Conclusion 
In the present study tualang honey supplementation has resulted in an improvement of the renal profile 
suggesting therefore its renoprotective effect. However the histopathological examination of the kidneys 
revealed similar changes to that of the rat models fed with high cholesterol diet and this may be related to 
the dose of honey used in the study. Additionally tualang honey showed improvement in triglyceride and 
TC levels indicating its lipid lowering activities at 1 week. 
The 12% cholesterol diet of 6 weeks duration in the animal model did induce some features of NASH 
with dyslipidaemia and abnormal liver profile but no effects were documented on the plasma glucose, 
serum insulin and HOMA-IR index. The pancreas also revealed no abnormality histologically. Tualang 
honey supplementation for the 6 weeks duration along with the 12% cholesterol diet resulted in 
improvement of the liver enzymes but exhibited no effect on the dyslipidaemia and did not improve the 
histopathological changes of the liver. Further studies are needed to explain the higher serum insulin 
levels and HOMA-IR with the honey supplementation. Also a longer duration of the high cholesterol diet 
administration would perhaps results in more obvious histological changes compatible to NASH. 
Additionally the dosage and duration of honey supplementation are subjected to further studies. 
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